The randomized, double-blind Anti-TNF Therapy Against Congestive Heart failure study was conducted in patients with moderate-to-severe heart failure, in whom infliximab therapy for 6 weeks did not result in symptom improvement and the risk of heart failure aggravation was increased when infliximab was administered at a high dose (10 mg/kg) [76]. The gene discussed is TNF; the disease is heart failure.